These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29397879)

  • 1. Systematic Second-look Surgery Plus HIPEC in Patients Without Evidence of Recurrence, at High Risk of Carcinomatosis After Colorectal Cancer Resection.
    Serrano Del Moral Á; Pérez Viejo E; Manzanedo Romero I; Rodríguez Caravaca G; Pereira Pérez F
    Cir Esp (Engl Ed); 2018 Feb; 96(2):96-101. PubMed ID: 29397879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis.
    Elias D; Honoré C; Dumont F; Ducreux M; Boige V; Malka D; Burtin P; Dromain C; Goéré D
    Ann Surg; 2011 Aug; 254(2):289-93. PubMed ID: 21709543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis.
    Elias D; Goéré D; Di Pietrantonio D; Boige V; Malka D; Kohneh-Shahri N; Dromain C; Ducreux M
    Ann Surg; 2008 Mar; 247(3):445-50. PubMed ID: 18376188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.
    Delhorme JB; Triki E; Romain B; Meyer N; Rohr S; Brigand C
    J Visc Surg; 2015 Jun; 152(3):149-54. PubMed ID: 25650364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.
    Goéré D; Glehen O; Quenet F; Guilloit JM; Bereder JM; Lorimier G; Thibaudeau E; Ghouti L; Pinto A; Tuech JJ; Kianmanesh R; Carretier M; Marchal F; Arvieux C; Brigand C; Meeus P; Rat P; Durand-Fontanier S; Mariani P; Lakkis Z; Loi V; Pirro N; Sabbagh C; Texier M; Elias D;
    Lancet Oncol; 2020 Sep; 21(9):1147-1154. PubMed ID: 32717180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
    Ripley RT; Davis JL; Kemp CD; Steinberg SM; Toomey MA; Avital I
    Trials; 2010 May; 11():62. PubMed ID: 20500867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives?
    Cortes-Guiral D; Elias D; Cascales-Campos PA; Badía Yébenes A; Guijo Castellano I; León Carbonero AI; Martín Valadés JI; Garcia-Foncillas J; Garcia-Olmo D
    World J Gastroenterol; 2017 Jan; 23(3):377-381. PubMed ID: 28210074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-look surgery plus HIPEC for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Should we resect the initial anastomosis? An observational study.
    Cloutier AS; Faron M; Honoré C; Goéré D; Dumont F; Vittadello F; Élias D
    Eur J Surg Oncol; 2015 Aug; 41(8):1068-73. PubMed ID: 25921674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
    Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
    Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer.
    Graziosi L; Cantarella F; Mingrone E; Gunnellini M; Cavazzoni E; Liberati M; Donini A
    Ann Ital Chir; 2013; 84(5):551-6. PubMed ID: 24140896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
    Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
    Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
    World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis.
    Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH
    Ann Surg Oncol; 2016 Mar; 23(3):833-41. PubMed ID: 26442921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
    Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
    Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-look Surgery Detects Low Volume Recurrent Disease Following Cytoreductive Surgery for Peritoneal Carcinomatosis.
    Matar A; Altoukhi K; Tse A; Sohn J; Alzahrani N; Morris DL
    Anticancer Res; 2022 Feb; 42(2):1001-1006. PubMed ID: 35093900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of colorectal cancer patients at high risk of peritoneal metastases.
    Shariff U; Seretis C; Youssef H
    J BUON; 2015 May; 20 Suppl 1():S71-9. PubMed ID: 26051336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?
    Honoré C; Goéré D; Macovei R; Colace L; Benhaim L; Elias D
    J Visc Surg; 2016 Apr; 153(2):101-7. PubMed ID: 26698380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.